Related Experiment Videos
Visual function improvement in patients with macroprolactinomas treated with bromocriptine.
R L Lesser1, J D Zheutlin, D Boghen
1Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut 06510.
American Journal of Ophthalmology
|May 15, 1990
Summary
Bromocriptine effectively treats visual field defects caused by prolactin-secreting macroadenomas, improving vision without surgery. Long-term, indefinite bromocriptine therapy is recommended, requiring ongoing monitoring.
Area of Science:
- Neuro-oncology
- Endocrinology
- Ophthalmology
Background:
- Prolactin-secreting macroadenomas can cause significant visual field defects.
- Surgical or radiation treatments carry inherent risks and potential side effects.
Observation:
- Eight patients with visual field defects secondary to prolactin-secreting macroadenomas were studied.
- Patients received bromocriptine treatment, avoiding surgery or radiation.
Findings:
- Bromocriptine treatment led to improved visual function in all studied patients.
- No surgical or radiation interventions were required for these patients.
Implications:
- Bromocriptine is recommended as a primary treatment for prolactin-secreting macroadenomas.
- Effective bromocriptine therapy necessitates indefinite treatment and regular neuro-ophthalmologic, endocrine, and imaging follow-up.